SATB1 and primary cutaneous T-cell non-Hodgkin lymphoma: A study of CTCL in mice illustrated that methyltransferase inhibitors could restore SATB1 function in the Sézary cell line (50), and the usage of this target drug possibly abrogates malignant expansion in CTCL dogs.